Gwestrookietraders Disclaimer
20M O/S Per Jan 13 News: http://www.newswire.ca/en/releases/archive/January2011/13/c2262.html
5M Float - Per CEO Email on 01/18/11: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58905651
5M Held by CEO: http://finance.yahoo.com/q/ir?s=CPBM.OB+Insider+Roster
Transfer Agent:
Pacific Stock Transfer Co.
4045 South Spencer St., Suite 403
Las Vegas, NV, 89119
702-361-3033
http://www.pacificstocktransfer.com
info@pacificstocktransfer.com
Cyplasin Biomedical Ltd. (Cyplasin) is a biotechnology development-stage company and has not generated any revenues from its technologies. On February 7, 2009, the Company entered into a licensing agreement with Bioxen for further development of the Cyplasin product. Under terms of the agreement, Bioxen received an exclusive license to further develop the Cyplasin product and commercialize the intellectual property held by its company. On July 1, 2009, the Company entered into a license agreement with Arizona based C-Virionics Corporation for their Hepatitis C prophylactic vaccine. On August 1, 2009, the Company entered into an IP Asset Transfer Agreement with Bioxen Ltd., which effectively terminated the previous license agreement and in consideration for cancellation of Bioxen shares in the Company, returned the Cyplasin patents back to Bioxen
0 comments:
Post a Comment
Comment on Your stock Pick